Navigation Links
Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
Date:4/4/2008

both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
2. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
3. Angiotech to participate in Lehman Brothers Healthcare Conference
4. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
5. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
6. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
7. Angiotech announces results for the fourth quarter ended December 31, 2007
8. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
10. Angiotech and Symphony Medical Announce Licensing Agreement
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and SOUTH SAN FRANCISCO, Calif. ... the venture arm of Baxter International Inc. (NYSE: ... LLC ("VPD") today announced the formation of Vitesse Biologics, ... by Baxter Ventures to focus on the development of ... hematology, and oncology. Following the spin-off of Baxter BioScience ...
(Date:6/1/2015)... /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") today ... the ERA-EDTA Congress in London, England ... First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects ... (CKD); a Post-hoc Analysis of Patients from the ASSERT, ... Kam Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension ...
(Date:6/1/2015)... , June 1, 2015   Epic Sciences, ... develops products and offerings to personalize and advance the ... has expanded the available credit under its existing credit ... amended agreement increases the available capacity of the facility ... the maturity by 27 months to April 1, 2019. ...
(Date:6/1/2015)... , May 29, 2015 Research ... the addition of the "2015 Strategies ... report to their offering. This ... European immunoprotein diagnostic market, including emerging tests, ... strategic profiles of leading suppliers. ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Two-dimensional, "sheet-like" nanostructures are commonly employed in biological ... properties have inspired interest in materials such as ... largest two-dimensional polymer crystal self-assembled in water to ... complexity of biological systems with the durable architecture ...
... ... Footprint , ... -- LS9, Inc ., the Renewable Petroleum Company™, today announced that its UltraClean ... was officially registered by the United States Environment Protection Agency (EPA). As a ...
... new method for identifying genetic variation, including mutations, in ... an important research tool that will lead to the ... method, which is directly applicable to cell preparations and ... genetic variation in patient samples from a variety of ...
Cached Biology Technology:Berkeley Lab scientists create 'molecular paper' 2LS9's UltraClean Diesel™ Receives EPA Registration 2Mutations directly identifiable in active genes 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Michigan researchers have discovered how to measure the ... cancer cells, a breakthrough that will revolutionize scientists' ... environment. , A team led by U-M ... multi-walled carbon nanotubes---one of the most promising nanomaterials ...
... Biotechnology, scientists and doctors with the Physicians Committee for ... to grow live cells in the laboratory. At issue ... obtained by puncturing the heart of a fetal calf ... cells in a medium free of animal serum, enabling ...
... have discovered that our ears use the most efficient ... brooks to wailing babies. These results represent a significant ... for transmission to the brain, according to the authors, ... Views" editorial in the Feb. 23 issue of Nature. ...
Cached Biology News:Carbon nanotube absorption measured in worms, cancer cells 2Carnegie Mellon scientists show brain uses optimal code for sound 2Carnegie Mellon scientists show brain uses optimal code for sound 3
Buffer used for mitocapture assays....
... CyScribe GFX Purification Kit, 25 ... CyDye labeled cDNA probesProvides efficient removal ... from labeling reactions with superior yields ... for the purification of cDNA labeled ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Biology Products: